Subtype
Gastric Carcinoma
CI-CAN-00002732Explore in graph →
183 active trials3 approved drugs37 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002732Explore in graph →
Clinical trials
586 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (65)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06645912 | Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy | completed | N/A | 46 | Erzincan Binali Yildirim University Mengucek Gazi Training and Research HospitalOTHER_GOV | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04253106 | Liquid Biopsies for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer(LISA-HDGC) | completed | N/A | 16 | Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Sep 23, 2024 |
| clinicaltrials |
| NCT02891447 | Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04065139 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study(PIPAC EstoK 01) | completed | Phase 2 | 66 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03647969 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | completed | Phase 2 | 262 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03852251 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | completed | Phase 1 / Phase 2 | 338 | AkesoINDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | completed | Phase 1 | 175 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 31, 2024 | clinicaltrials |
| NCT06342427 | Stomach Cancer Exosome-based Detection(DESTINEX) | completed | — | 809 | City of Hope Medical CenterOTHER | 2 | Jul 8, 2024 | clinicaltrials |
| NCT06477562 | Surveillance Endoscopy After Proximal Gastriectomy With Double Tract Reconstruction. | completed | — | 160 | Saint Vincent's Hospital, KoreaOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04808791 | iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 7 | AHS Cancer Control AlbertaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06250075 | Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer(PRONIC-G) | completed | N/A | 88 | Universidade Federal do AmazonasOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04768218 | BLI for the Diagnosis of Precancerous Conditions | completed | — | 102 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT02830594 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 14 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03990025 | Linked Color Imaging vs White Light Imaging for Detection of Gastric Cancer Precursors | completed | N/A | 90 | Changi General HospitalOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT05083338 | Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy | completed | — | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04074343 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | completed | Phase 1 | 20 | University of California, IrvineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06238752 | First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC(RENMIN-213) | completed | Phase 2 | 33 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03196232 | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | completed | Phase 2 | 3 | George Albert FisherOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | completed | Phase 2 | 18 | Ashwin SomasundaramOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT05997524 | Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer. | completed | Phase 2 | 60 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT03918499 | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 9 | City of Hope Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05671393 | the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma | completed | — | 801 | Fujian Medical UniversityOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03368196 | DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | completed | Phase 1 | 12 | Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo CompanyINDUSTRY | 1 | Nov 3, 2022 | clinicaltrials |
| NCT05334849 | Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy | completed | — | 80 | Lin ChenOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04047004 | Adjuvant PIPAC in Gastric Cancer Patients(PIPAC-OPC4) | completed | Phase 1 | 20 | Michael Bau MortensenOTHER | 2 | Oct 6, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT01938326 | Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG) | completed | N/A | 86 | Seoul National University Bundang HospitalOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT04483349 | Assessment of What Patients and Healthcare Providers Value | completed | — | 397 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02335411 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | completed | Phase 2 | 318 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03409848 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma(INTEGA) | completed | Phase 2 | 97 | AIO-Studien-gGmbHOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT04602299 | Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors | completed | N/A | 2,000 | Changhai HospitalOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT01804998 | Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy | completed | N/A | 580 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 15, 2022 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT00591123 | Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia | completed | Phase 2 | 38 | Translational Oncology Research InternationalOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT02314117 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer(RAINFALL) | completed | Phase 3 | 645 | Eli Lilly and CompanyINDUSTRY | 20 | Aug 26, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04920747 | Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients(TandHER) | completed | — | 65 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02564367 | Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction(S-1 adjuvant) | completed | Phase 1 / Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 29, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Oct 18, 2024source: clinicaltrials